CD16a with oligomannose-type N-glycans is the only “low-affinity” Fc γ receptor that binds the IgG crystallizable fragment with high affinity in vitro

• Published in: The Journal of biological chemistry Vol. 293; no. 43; pp. 16842 - 16850
• Main Authors: Subedi, Ganesh P., Barb, Adam W.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.10.2018; American Society for Biochemistry and Molecular Biology
• Subjects: antibody; Fc receptor; Fc-gamma receptor; Glycobiology and Extracellular Matrices; Glycosylation; GPI-Linked Proteins - metabolism; HEK293 Cells; Humans; Immunoglobulin Fc Fragments - metabolism; Immunoglobulin G - chemistry; Immunoglobulin G - metabolism; In Vitro Techniques; N-linked glycosylation; Oligosaccharides - metabolism; Polysaccharides - metabolism; post-translational modification (PTM); Protein Binding; Receptors, IgG - metabolism; post-translational modification (PTM); Fc receptor; antibody; N-linked glycosylation; Fc-gamma receptor
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA118.004998

Fc γ receptors (FcγRs) bind circulating IgG (IgG1) at the surface of leukocytes. Antibodies clustered at the surface of a targeted particle trigger a protective immune response through activating FcγRs. Three recent reports indicate that the composition of the asparagine-linked carbohydrate chains (N-glycans) of FcγRIIIa/CD16a impacted IgG1-binding affinity. Here we determined how N-glycan composition affected the affinity of the “low-affinity” FcγRs for six homogeneous IgG1 Fc N-glycoforms (G0, G0F, G2, G2F, A2G2, and A2G2F). Surprisingly, CD16a with oligomannose N-glycans bound to IgG1 Fc (A2G2) with a KD = 1.0 ± 0.1 nm. This affinity represents a 51-fold increase over the affinity measured for CD16a with complex-type N-glycans (51 ± 8 nm) and is comparable with the affinity of FcγRI/CD64, the sole “high-affinity” FcγR. CD16a N-glycan composition accounted for increases in binding affinity for the other IgG1 Fc glycoforms tested (10–50-fold). This remarkable sensitivity could only be eliminated by preventing glycosylation at Asn162 with an Asn-to-Gln mutation; mutations at the four other N-glycosylation sites preserved tighter binding in the Man5 glycoform. None of the other low-affinity FcγRs showed more than a 3.1-fold increase upon modifying the receptor N-glycan composition, including CD16b, which differs from CD16a by only four amino acid residues. This result indicates that CD16a is unique among the low-affinity FcγRs, and modifying only the glycan composition of both the IgG1 Fc ligand and receptor provides a 400-fold range in affinities.